Cytosorbents Corp.
Key Metrics
- Previous Close
- $0.36
- 52-Week Range
- $0.30 – $1.04
- Market Cap
- $19.55M
- P/E (TTM)
- —
- EPS (TTM)
- -0.25
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- -336.21%
- Return on Assets
- -17.12%
- Gross Margin
- 71.61%
- Operating Margin
- -24.58%
- Profit Margin
- -48.94%
- Current Ratio
- 0.66
- Debt/Equity
- —
- Total Debt
- $29.43M
- Free Cash Flow
- $-3.51M
- Revenue Growth
- 0.20%
- Earnings Growth
- —
- Enterprise Value
- $44.56M
Market Snapshot
About
Cytosorbents Corp. is a medical device company focused on critical care therapies. Headquartered in Monmouth Junction, New Jersey, the company develops and markets blood purification technologies. Its flagship product, CytoSorb, is designed to reduce cytokine levels in the bloodstream during severe inflammatory conditions such as sepsis and cardiac surgery. The device is approved and used in multiple countries, particularly in Europe, for treating critically ill patients.